Summary
58 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 40% this fiscal year.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.9 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 7.5% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 40%.
Growth in detailDoes it make money?
ReasonablyWhere 100 CAD of revenue goes
- Cost of sales 82 CAD
- Sales and administration 23 CAD
- Taxes and other 2.7 CAD
- Net profit 6.1 CAD
Net profit, industry median (Medical - Care Facilities) 6.7 CAD
Out of every 100 CAD of revenue, 6.1 CAD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 11.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.87%
- Paid out of profit
- 41%
- Raised in a row
- 1 year
You receive $0.37 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.